PMID- 35286799
OWN - NLM
STAT- MEDLINE
DCOM- 20221021
LR  - 20230103
IS  - 2287-285X (Electronic)
IS  - 2287-2728 (Print)
IS  - 2287-2728 (Linking)
VI  - 28
IP  - 4
DP  - 2022 Oct
TI  - Old and new classes of glucose-lowering agents as treatments for non-alcoholic 
      fatty liver disease: A narrative review.
PG  - 725-738
LID - 10.3350/cmh.2022.0015 [doi]
AB  - Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic 
      liver disease with a global prevalence of about 55% in people with type 2 
      diabetes mellitus (T2DM). T2DM, obesity and NAFLD are three closely inter-related 
      pathological conditions. In addition, T2DM is one of the strongest clinical risk 
      factors for the faster progression of NAFLD to non-alcoholic steatohepatitis 
      (NASH), cirrhosis and hepatocellular carcinoma. Increasing evidence suggests that 
      newer classes of glucose-lowering drugs, such as peroxisome 
      proliferator-activated receptor agonists, glucagon-like peptide-1 receptor 
      agonists, dipeptidyl peptidase-4 inhibitors or sodium-glucose cotransporter-2 
      inhibitors, could reduce the rates of NAFLD progression. This narrative review 
      aims to briefly summarize the recent results from randomized controlled trials 
      testing the efficacy and safety of old and new glucose-lowering drugs for the 
      treatment of NAFLD or NASH in adults both with and without coexisting T2DM.
FAU - Miao, Lei
AU  - Miao L
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou, China.
FAU - Xu, Jing
AU  - Xu J
AD  - Department of Endocrinology, The Second Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou, China.
FAU - Targher, Giovanni
AU  - Targher G
AD  - Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, 
      University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, 
      Italy.
FAU - Byrne, Christopher D
AU  - Byrne CD
AD  - Southampton National Institute for Health Research Biomedical Research Centre, 
      University Hospital Southampton, Southampton General Hospital, Southampton, UK.
FAU - Zheng, Ming-Hua
AU  - Zheng MH
AD  - NAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of 
      Wenzhou Medical University, Wenzhou, China.
AD  - Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver 
      Disease in Zhejiang Province, Wenzhou, China.
LA  - eng
GR  - 82070588/National Natural Science Foundation of China/
GR  - S2032102600032/High Level Creative Talents from the Department of Public Health 
      in Zhejiang Province/
GR  - Project of New Century 551 Talent Nurturing in Wenzhou/
GR  - University School of Medicine of Verona/
GR  - IS-BRC-20004/Southampton NIHR Biomedical Research Centre/
PT  - Journal Article
PT  - Review
DEP - 20220314
PL  - Korea (South)
TA  - Clin Mol Hepatol
JT  - Clinical and molecular hepatology
JID - 101586730
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - IY9XDZ35W2 (Glucose)
RN  - 0 (Peroxisome Proliferator-Activated Receptors)
RN  - EC 3.4.14.- (Dipeptidyl-Peptidases and Tripeptidyl-Peptidases)
RN  - 9NEZ333N27 (Sodium)
SB  - IM
MH  - Humans
MH  - *Non-alcoholic Fatty Liver Disease/complications/drug therapy/epidemiology
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Glucagon-Like Peptide-1 Receptor/therapeutic use
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
MH  - Glucose/therapeutic use
MH  - Peroxisome Proliferator-Activated Receptors/therapeutic use
MH  - Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/therapeutic use
MH  - Sodium
PMC - PMC9597221
OTO - NOTNLM
OT  - Glucose-lowering drugs
OT  - Metabolic dysfunctionassociated fatty liver disease
OT  - Non-alcoholic fatty liver disease
OT  - Type 2 diabetes mellitus
COIS- Conflicts of Interest The authors have no conflicts to disclose.
EDAT- 2022/03/15 06:00
MHDA- 2022/10/22 06:00
PMCR- 2022/10/01
CRDT- 2022/03/14 19:33
PHST- 2022/01/15 00:00 [received]
PHST- 2022/03/11 00:00 [accepted]
PHST- 2022/03/15 06:00 [pubmed]
PHST- 2022/10/22 06:00 [medline]
PHST- 2022/03/14 19:33 [entrez]
PHST- 2022/10/01 00:00 [pmc-release]
AID - cmh.2022.0015 [pii]
AID - cmh-2022-0015 [pii]
AID - 10.3350/cmh.2022.0015 [doi]
PST - ppublish
SO  - Clin Mol Hepatol. 2022 Oct;28(4):725-738. doi: 10.3350/cmh.2022.0015. Epub 2022 
      Mar 14.